This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?
by Urmimala Biswas
Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
by Zacks Equity Research
BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up
by Zacks Equity Research
QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.
Phibro's Q1 Earnings Top Estimates, Stock Up, Net Sales Surge Y/Y
by Zacks Equity Research
PAHC delivers strong growth across all its segments in the first quarter of fiscal 2025.
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall
by Zacks Equity Research
CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.
CVS Health Q3 Earnings & Revenues Beat, Stock Rises in Premarket
by Zacks Equity Research
CVS' third-quarter 2024 results reflect strong performance in the Health Services and Pharmacy & Consumer Wellness segments.
MASI Stock Gains Following Q3 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
Masimo's third-quarter 2024 results continue to benefit from the strength in its Healthcare business.
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
by Zacks Equity Research
CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading.
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut
by Zacks Equity Research
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.
Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure
by Zacks Equity Research
IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter.
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts
by Zacks Equity Research
Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.
INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.
Hologic Q4 Earnings Lag, Revenues Top, Stock Down in Aftermarket
by Zacks Equity Research
HOLX's fiscal 2024 fourth-quarter results underscore the durable growth of its businesses.
Insulet Stock Gains From Expansion Strategies, Innovation
by Zacks Equity Research
PODD continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign.
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel
by Zacks Equity Research
QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Stock Gains From Market Expansion, Innovation
by Zacks Equity Research
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
by Zacks Equity Research
Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.
Teleflex Q3 Earnings Top, Stock Falls on Lowered 2024 Revenue Outlook
by Zacks Equity Research
TFX benefits from a diversified product portfolio in the third quarter of 2024, with strength in the Vascular Access and Interventional segments.
The Zacks Analyst Blog The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific
by Zacks Equity Research
The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific are included in this Analyst Blog.
OMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised
by Zacks Equity Research
Omnicell continues its trend of impressive results in the third quarter of 2024.
Looking for a Growth Stock? 3 Reasons Why Boston Scientific (BSX) is a Solid Choice
by Zacks Equity Research
Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market.
The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction
by Zacks Equity Research
mazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.
Envista Stock Climbs on Q3 Earnings and Revenue Beat, Margins Crash
by Zacks Equity Research
NVST delivers better-than-expected top and bottom-line performance in the third quarter of 2024.